Semble
UK healthtech company providing outpatient-care management platforms, raising £30m Series C to expand across Europe.
Last refreshed: 7 June 2026 · Appears in 1 active topic
How is Semble expanding its outpatient management platform across Europe after the Series C?
- What does Semble's healthcare management platform do?
- Semble provides cloud-native practice-management software for outpatient and specialist clinic operators, covering appointment scheduling, patient records, billing and workflow management.Source: Semble Series C announcement, June 2026
- How much has Semble raised and who are its investors?
- Semble raised £30m in a Series C in June 2026, led by Revaia, with Octopus Ventures, Mercia and Partech also investing.Source: Series C press release, June 2026
- Which countries is Semble expanding into after the Series C?
- Semble is expanding across Europe, with France named as an early target market following the June 2026 Series C.Source: Series C announcement, June 2026
Background
Semble is a UK healthcare-management platform serving outpatient providers, raising £30m in a Series C on 4 June 2026 led by Revaia, with Octopus Ventures, Mercia and Partech participating. The company provides practice-management software for outpatient and specialist clinic operators, covering appointment scheduling, patient records, billing and workflow management across a fragmented provider market. The round includes plans for expansion across Europe, with France named as an early target.
Outpatient healthcare management is a historically underdeveloped segment for software investment, with many independent specialist clinics and outpatient providers still running on legacy systems or paper-based workflows. Semble's platform targets this fragmentation by offering cloud-native practice-management tooling to the growing private and semi-private outpatient sector in the UK and Europe. The European expansion reflects a broader trend of UK healthtech companies using their NHS-adjacent credibility as a reference customer base to open European markets.
The Series C investor roster spans UK (Octopus Ventures, Mercia) and continental European (Revaia, Partech) VCs, which is operationally useful for a company planning cross-border expansion. Revaia, a growth-equity fund with a strong European healthcare portfolio, taking the lead at Series C gives Semble access to relationships with European health system operators and regulatory expertise across multiple jurisdictions.